Hormone replacement therapy to maintain cognitive function in women with dementia
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: As estrogens have been shown to have several potentially beneficial effects on the central nervous system, it is biologically plausible that maintaining high levels of estrogens in postmenopausal women by means of estrogen replacement therapy (ERT) could be protective against cognitive decline in women with Alzheimer's disease (AD) or other dementia syndromes. OBJECTIVES: To investigate the effects of ERT (estrogens only) or HRT (estrogens combined with a progestagen) compared with placebo in randomized controlled trials (RCTs) on cognitive function of postmenopausal women with dementia. SEARCH STRATEGY: The Cochrane Dementia and Cognitive Improvement Group Specialized Register, which contains records from many medical databases, The Cochrane Library, EMBASE, MEDLINE, CINAHL, PsycINFO and LILACS were searched on 7 November 2007 using the terms ORT, PORT, ERT, HRT, estrogen*, oestrogen* and progesterone*. SELECTION CRITERIA: All double-blind randomized controlled trials (RCTs) into the effect of ERT or HRT for cognitive function with a treatment period of at least two weeks in postmenopausal women with AD or other types of dementia. DATA COLLECTION AND ANALYSIS: Abstracts of the references retrieved by the searches were read by two reviewers (EH and KY) independently in order to discard those that were clearly not eligible for inclusion. The two reviewers studied the full text of the remaining references and independently selected studies for inclusion. Any disparity in the ensuing lists was resolved by discussion with all reviewers in order to arrive at the final list of included studies. The selection criteria ensured that the blinding and randomization of the included studies was adequate. The two reviewers also assessed the quality of other aspects of the included trials. One reviewer (EH) extracted the data from the studies, but was aided and checked by JB from Cochrane. MAIN RESULTS: A total of seven trials including 351 women with AD were analysed. Because different drugs were used at different studies it was not possible to combine more than two studies in any analysis.On a clinical global rating, clinicians scored patients taking CEE as significantly worse compared with the placebo group on the Clinical Dementia Rating scale after 12 months (overall WMD = 0.35, 95% CI = 0.01 to 0.69, z = 1.99, P < 0.05).Patients taking CEE had a worse performance on the delayed recall of the Paragraph Test (overall WMD = -0.45, 95% CI = -0.79 to -0.11, z = 2.60, P < 0.01) after one month than those taking placebo. They had a worse performance on Finger Tapping after 12 months (WMD = -3.90, 95% CI = -7.85 to 0.05, z = 1.93, P < 0.05).Limited positive effects were found for the lower dosage of CEE (0.625 mg/day) which showed a significant improvement in MMSE score only when assessed at two months, and disappeared after correction for multiple testing. No significant effects for MMSE were found at longer end points (3, 6 and 12 months of treatment). With a dosage of 1.25 mg/d CEE, short-term significant effects were found for Trial-Making test B at one month and Digit Span backward at four months. After two months of transdermal diestradiol (E2) treatment, a highly significant effect was observed for the word recall test (WMD = 6.50, 95% CI = 4.04 to 8.96, z = 5.19, P < 0.0001). No other significant effects were found for other outcomes measured. AUTHORS' CONCLUSIONS: Currently, HRT or ERT for cognitive improvement or maintenance is not indicated for women with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Bias in treatment assignment in controlled clinical trials
Chalmers, T. C., Celano, P., Sacks, H. S., & Smith, H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092204 · Cited by 864
Rates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses
Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., Brayne, C., Copeland, J. R. M., Dartigues, J.-F., Kragh-Sorensen, P., et al. (1999) · Neurology · doi:10.1212/wnl.52.1.78 · Cited by 758
Yoon, B.-K., Kim, D. K., Kang, Y., Kim, J.-W., Shin, M.-H., & Na, D. L. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04666-6 · Cited by 35
Research works printed but not linked: 47
- Asthana, 1999, Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with AD: results of a placebo-controlled, double-blind pilot study, Psychoneuroendocrinology, 24, 657, 10.1016/S0306-4530(99)00020-7 · DOI · Paper page
- Asthana S Baker LD Craft S Stanczyk FZ Veith RC Raskind MA Plymate SR High-dose estradiol improves cognition for women with AD: results of a randomized study Neurology 2001 605 12 · DOI · Paper page
- Birge, 1997, The role of estrogen in the treatment of Alzheimer's disease, Neurology, 48, S36, 10.1212/WNL.48.5_Suppl_7.36S · DOI · Paper page
- Henderson, 2000, Estrogen for Alzheimer's disease in women, Neurology, 54, 295, 10.1212/WNL.54.2.295 · DOI · Paper page
- Honjo, 1995, Senile dementia-Alzheimer's type and estrogen, Horm. Metab. Res., 27, 204, 10.1055/s-2007-979941 · DOI · Paper page
- Caldwell, 1952, Evaluation of psychologic effects of sex hormone administration in aged women: results of therapy after 6 months, Journal of Gerontology, 7, 228, 10.1093/geronj/7.2.228 · DOI · Paper page
- Mulnard, 2000, Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease, JAMA, 283, 1007, 10.1001/jama.283.8.1007 · DOI · Paper page
- Wang, 2000, Effects of estrogen on cognition, mood, and cerebral blood flow in AD, Neurology, 54, 2061, 10.1212/WNL.54.11.2061 · DOI · Paper page
- Zhang, 2006, Quantitative evaluation of the intervention al effect of estrogen on Alzheimer's disease, Chinese Journal of Clinical Rehabilitation, 10, 37
- Fillit, 1986, Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type, Psychoneuroendocrinology, 11, 337, 10.1016/0306-4530(86)90019-3 · DOI · Paper page
- Fillit, 1994, Estrogens in the Pathogenesis and Treatment of Alzheimer's Disease in Postmenopausal Women, Annals of the New York Academy of Sciences, 743, 233, 10.1111/j.1749-6632.1994.tb55795.x · DOI
- Honjo, 1989, In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type), Journal of Steroid Biochemistry, 34, 521, 10.1016/0022-4731(89)90137-4 · DOI · Paper page
- Kantor, 1973, Estrogen for older women, American Journal of Obstetrics and Gynecology, 4, 31
- Ohkura, 1994, Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type, Endocrine Journal, 41, 361, 10.1507/endocrj.41.361 · DOI · Paper page
- Ohkura, 1994b, Low-dose estrogen replacement therapy for Alzheimer disease in women, Menopause, 1, 125
- Ohkura, 1995, Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type 7 case reports, Dementia, 6, 99
- Rigaud, 2003, No additional benefit of HRT on response to rivastigmine in menopausal women with AD, Neurology, 60, 148, 10.1212/WNL.60.1.148-a · DOI · Paper page
- Al-Azzawi, 2008, Pulsatile nasal administration of estradiol for postmenopausal complaints
- American Psychiatric Association, 1999, Diagnostic and Statistical Manual of Mental Disorders
- Barrett-Connor, 1991, Postmenopausal estrogen and prevention bias. Postmenopausal estrogen and prevention bias, Annals of Internal Medicine, 115, 455, 10.7326/0003-4819-115-6-455 · DOI · Paper page
- Christie, 1990, Reduced plasma oestrogen stimulated neurophysin and delayed response to oestrogen challenge in AD, Psych Med, 20, 773, 10.1017/S003329170003645X · DOI
- Col, 2001, Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk, Journal of Clinical Oncology, 19, 2357, 10.1200/JCO.2001.19.8.2357 · DOI
- Fratiglioni, 2000, Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group, Neurology, 54, S10
- Gibbs, 2008, Animal studies that support estrogen effects on cognitive performance and the cholinergic basis of the critical period hypothesis
- Henderson, 2008, The critical window hypothesis: hormone exposure and cognitive outcomes after menopause
- Hogervorst, 2000, The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis, Neuroscience, 101, 485, 10.1016/S0306-4522(00)00410-3 · DOI · Paper page
- Hogervorst, 2007, Should surgically menopausal women be treated with estrogens to decrease the risk for dementia?, Neurology, Invited Editorial, 69, 1070
- Huppert, 1997, Ageing, cognition and dementia, Age and Ageing, Dec 26, 20, 10.1093/ageing/26.suppl_4.20 · doi:10.1093/ageing/26.suppl_4.20
- LeBlanc, 2001, Hormone replacement therapy and cognition, JAMA, 285, 1489, 10.1001/jama.285.11.1489 · DOI · Paper page
- Lethaby, 2008, Hormone replacement therapy for cognitive function in postmenopausal women, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003122.pub2 · DOI · Paper page
- Matthews, 1996, Prior to use of estrogen replacement therapy: are users healthier than nonusers ?, American Journal of Epidemiology, 143, 971, 10.1093/oxfordjournals.aje.a008678 · DOI · Paper page
- McEwen, 1997, Ovarian steroids and the brain implications for cognition and aging, Neurology, 48, S14, 10.1212/WNL.48.5_Suppl_7.8S · DOI · Paper page
- McKhann, 1984, Clinical Diagnosis of Alzheimer’s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology, 4, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- Nappi, 1999, Memory functioning at menopause: impact of age in ovariectomized women, Gynecologic and Obstetric Investigation, 47, 29, 10.1159/000010058 · DOI · Paper page
- Paganini-Hill, 2001, Hormone replacement therapy and stroke: risk, protection or no effect? Hormone replacement therapy and stroke: risk, protection or no effect?, Maturitas, 38, 243, 10.1016/S0378-5122(01)00167-0 · DOI
- Rodríguez, 2001, Thiamine for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001498 · DOI
- Schulz, 1995, Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA, 273, 408, 10.1001/jama.1995.03520290060030 · DOI
- Schumaker, 1998, The WHIMS: a trial of estrogen therapy in preventing and slowing the progression of dementia, Control Clin Trials, 19, 604
- Shumaker, 2004, Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study, JAMA, 291, 2947, 10.1001/jama.291.24.2947 · DOI · Paper page
- Silva, 2001, Estrogen and the aging brain, Maturitas, 38, 100, 10.1016/S0378-5122(00)00195-X · DOI
- Toran-Allerand, 2000, Estrogen as a treatment for AD: commentary, JAMA, 284, 307, 10.1001/jama.284.3.307-a · doi:10.1001/jama.284.3.307-a
- Wegienka, 2006, Menopausal hormone therapy in a health maintenance organization before and after women's health initiative hormone trials termination, Journal of Women's Health, 15, 369, 10.1089/jwh.2006.15.369 · DOI
- Yaffe, 1998, Estrogen therapy in postmenopausal women, Journal of the American Medical Association, 279, 688, 10.1001/jama.279.9.688 · DOI · Paper page
- Yaffe, 1998, Serum estrogen levels, cognitive performance and risk of cognitive decline in older community women, Journal of the American Geriatrics Sociaty, 46, 816, 10.1111/j.1532-5415.1998.tb02713.x · DOI · Paper page
- Yaffe, 2000, Cognitive decline in women with relation to non-protein bound estradiol concentrations, Lancet, 356, 708, 10.1016/S0140-6736(00)02628-3 · DOI · Paper page
- Yesufu, 2007, Meta-analyses of the effect of hormone treatment on cognitive function in postmenopausal women, Women’s Health invited review, 3, 173
- Hogervorst, 2002, Hormone replacement therapy to maintain cognitive function in women with dementia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003799 · DOI
Cited by
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Long term hormone therapy for perimenopausal and postmenopausal women
Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J. A., & Lamberts, Q. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub2 · Cited by 582
Long-term hormone therapy for perimenopausal and postmenopausal women
Marjoribanks, J., Farquhar, C., Roberts, H., Lethaby, A., & Lee, J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub5 · Cited by 424
O’Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 354
Metadata
- Authors
- Hogervorst, E., Yaffe, K., Richards, M., & Huppert, F. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2009-01-21
- Volume
- 2010
- Issue
- 1
- Pages
- CD003799-CD003799
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1706937218
- Cited by
- 153
- References
- 4
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hormone replacement therapy to maintain cognitive function in women with dementia. https://app.cochat.ai/papers/10.1002/14651858.cd003799.pub2
- The paper
- Hogervorst, E., Yaffe, K., Richards, M., & Huppert, F. A. (2009). Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd003799.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.